1345009-45-1

1345009-45-1 structure
1345009-45-1 structure
  • Name: Vantictumab
  • Chemical Name: Vantictumab
  • CAS Number: 1345009-45-1
  • Molecular Formula:
  • Molecular Weight:
  • Catalog: Signaling Pathways Stem Cell/Wnt Wnt
  • Create Date: 2023-02-22 12:01:04
  • Modify Date: 2024-04-06 14:16:52
  • Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2].

Name Vantictumab
Description Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2].
Related Catalog
Target

FZD1/2/5/7/8[1][2].

References

[1]. Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38(3):821-830.  

[2]. Diamond JR, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184(1):53-62.  

No Any Chemical & Physical Properties